Biotech Values

[DewDiligence]

Xarelto addendum: This drug has the potential to move the needle materially even for a company as large as JNJ:

• 800,000 hip- and knee-replacement surgeries each year in the US alone.

• Above number will more than double during next two decades. (Boomers aren’t getting any younger!)

• VTE prevention following hip/knee replacement is only the tip of the iceberg of indications where Xarelto could be utilized.

• No oral anticoagulant has been approved by the FDA since warfarin in 1954!